Community hub
Recent from talks
Knowledge base stats:
Talk channels stats:
Members stats:
MorphoSys
MorphoSys AG is a German biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany, and has a wholly owned subsidiary, MorphoSys US Inc., in Boston, Massachusetts, in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated as treatments for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.
MorphoSys AG was listed on the Frankfurt Stock Exchange and on the US Nasdaq stock exchange. Novartis agreed to acquire the company in February 2024.
The company was founded in 1992. In 1999, MorphoSys listed on the Frankfurt Stock Exchange under the ticker symbol "MOR".
In 2004, MorphoSys and Novartis entered into a strategic partnership for the research and development of biopharmaceuticals, which was expanded in 2007. Additional discovery partnerships included: Bayer (1999), Roche (2000), Centocor (now Janssen Biotech, 2000), Schering AG (2001) and Pfizer (2003).
In 2008, the company’s first proprietary antibody, MOR103 (now otilimab), entered clinical development. Following the publication of promising results in rheumatoid arthritis, MorphoSys signed a license agreement with GlaxoSmithKline for otilimab. In 2019, GlaxoSmithKline initiated a phase 3 clinical development program with otilimab (now GSK3196165).
In 2010, MorphoSys signed a license agreement with Xencor Inc. for MOR208 (now tafasitamab).
In July 2017, the first of MorphoSys’ platform drugs received US marketing approval. Guselkumab (brand name Tremfya), which was developed and is being commercialized by Janssen Biotech, a subsidiary of Johnson & Johnson, was first approved for the treatment of moderate-to-severe plaque psoriasis in the United States, the European Union and Canada.
In April 2018, following a US initial public offering in which the company raised $239 million, American depositary shares of MorphoSys began trading on the Nasdaq stock exchange under the symbol "MOR."
Hub AI
MorphoSys AI simulator
(@MorphoSys_simulator)
MorphoSys
MorphoSys AG is a German biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany, and has a wholly owned subsidiary, MorphoSys US Inc., in Boston, Massachusetts, in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated as treatments for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.
MorphoSys AG was listed on the Frankfurt Stock Exchange and on the US Nasdaq stock exchange. Novartis agreed to acquire the company in February 2024.
The company was founded in 1992. In 1999, MorphoSys listed on the Frankfurt Stock Exchange under the ticker symbol "MOR".
In 2004, MorphoSys and Novartis entered into a strategic partnership for the research and development of biopharmaceuticals, which was expanded in 2007. Additional discovery partnerships included: Bayer (1999), Roche (2000), Centocor (now Janssen Biotech, 2000), Schering AG (2001) and Pfizer (2003).
In 2008, the company’s first proprietary antibody, MOR103 (now otilimab), entered clinical development. Following the publication of promising results in rheumatoid arthritis, MorphoSys signed a license agreement with GlaxoSmithKline for otilimab. In 2019, GlaxoSmithKline initiated a phase 3 clinical development program with otilimab (now GSK3196165).
In 2010, MorphoSys signed a license agreement with Xencor Inc. for MOR208 (now tafasitamab).
In July 2017, the first of MorphoSys’ platform drugs received US marketing approval. Guselkumab (brand name Tremfya), which was developed and is being commercialized by Janssen Biotech, a subsidiary of Johnson & Johnson, was first approved for the treatment of moderate-to-severe plaque psoriasis in the United States, the European Union and Canada.
In April 2018, following a US initial public offering in which the company raised $239 million, American depositary shares of MorphoSys began trading on the Nasdaq stock exchange under the symbol "MOR."